Immunotherapy
 /  Immunotherapy

Immunotherapy treatments work by stimulating a patient’s own immune system so that it can recognise and destroy cancer cells more effectively. These therapies modulate various components of the immune system.


Keytruda (pembrolizumab)

Keytruda is an immunotherapy which works with the body’s immune system to treat cancer.  Keytruda works by blocking a pathway that allows tumours to remain hidden from the immune system This helps to increase the ability of the body’s immune system to detect and fight tumor cells. Keytruda is also known as a checkpoint inhibitor.

Checkpoint inhibitors like Keytruda work by blocking the interaction between PD-L1 (a protein found on the surface of tumor cells) with PD-1 ( a receptor found on immune cells). Blocking the PD-1/PD-L1 connection allows a patient’s immune system to recognize and kill cancer cells.

Keytruda targets PD-1 and it works by “disarming” the tumour’s defences that block the the ability of T cells (white blood cells critical for the body’s immune responses) to attack the tumour.

Keytruda is administered intravenously every 3 weeks..

Keytruda is generally well tolerated but common side effects include fatigue and joint pain. Inflammation of major organs including intestines, lungs and liver can also occur.  It is important that patients tell their healthcare professionals about any side effects, even if they seem minor as inflammation may cause serious damage to your body and some inflammatory conditions may be life-threatening.

Keytruda is listed on the  Pharmaceutical Benefits Scheme (PBS) for first line treatment of BRAF wild-type advanced melanoma and as a 2nd line treatment of BRAF mutation positive advanced melanoma.


Opdivo® (nivolumab or “nivo”)

Opdivo is an immunotherapy which works with the body’s immune system to treat cancer.  Opdivo works by blocking a pathway that allows tumours to remain hidden from the immune system This helps to increase the ability of the body’s immune system to detect and fight tumor cells. Opdivo is also known as a checkpoint inhibitor.

Checkpoint inhibitors like Opdivo work by blocking the interaction between PD-L1 (a protein found on the surface of tumor cells) with PD-1 ( a receptor found on immune cells). Blocking the PD-1/PD-L1 connection allows a patient’s immune system to recognize and kill cancer cells.

Opdivo targets PD-1 and it works by “disarming” the tumour’s defences that block the the ability of T cells (white blood cells critical for the body’s immune responses) to attack the tumour.

Opdivo is administered intravenously every 2 weeks.

Opdivo is generally well tolerated but common side effects include fatigue and joint pain. Inflammation of major organs including intestines, lungs and liver can also occur.  It is important that patients tell their healthcare professionals about any side effects, even if they seem minor as inflammation may cause serious damage to your body and some inflammatory conditions may be life-threatening.

Opdivo is listed on the  Pharmaceutical Benefits Scheme (PBS) for first line treatment of BRAF wild-type advanced melanoma and as a 2nd line treatment of BRAF mutation positive advanced melanoma.


Yervoy® (ipilimumab or “ipi”)
Yervoy is an immunotherapy which works with the body’s immune system to treat cancer.  It is also known as a checkpoint inhibitor.

Yervoy is an antibody that targets CTLA-4 expressed on T-cells. CTLA-4 acts like a “brake” on the immune system.  By binding to CTLA-4, Yervoy releases the brake which allows the immune system to build its T-cell army to respond to cancer. T cells are white blood cells critical for the body’s immune responses.

Sometimes, in this process, the T-cells may cause inflammation of healthy cells and may result in serious side effects.  Side effects are generally manageable, if appropriately identified and treated.

Healthcare professionals use established guidelines to treat these side effects and the earlier the side effect is identified and treated, the better.  It is important that patients tell their healthcare professionals about any side effects, even if they seem minor, as inflammation may cause serious damage to your body and some inflammatory conditions may be life-threatening.

Common sites of inflammation include the skin (itchiness and rashes), the liver (causing liver enzymes to increase) and the bowel and stomach (causing diarrhoea).

Yervoy treatment consists of four infusions administered every 3 weeks (ie over 10 weeks) through an intravenous infusion (ie a drip).
Yervoy is listed on the Pharmaceutical Benefits Scheme (PBS) for advanced melanoma


Combination Treatment – Yervoy (ipilumimab) and Opdivo (nivolumab)

Opdivo and Yervoy target different checkpoint pathways (PD-1 and CTLA-4) to boost the immune system’s response to cancer.

When used together, they have a complementary effect.  In summary, Yervoy builds the T-cell army and Opdivo unleashes the T-cell army against the tumour.

Sometimes, in this process, the T-cells may cause inflammation of healthy cells and may result in serious side effects.  (See Yervoy and Opdivo side effects.)  More people experience serious side effects when treated with the combination of Opdivo and Yervoy than single agent treatment.   Side effects are generally manageable, if appropriately identified and treated. Healthcare professionals use established guidelines to treat these side effects and the earlier the side effect is identified and treated, the better.  It is important that patients tell their healthcare professionals about any side effects, even if they seem minor, as inflammation may cause serious damage to your body and some inflammatory conditions may be life-threatening.

The combination is Therapeutic Goods Administration (TGA) approved only for patients with Stage IV (metastatic) melanoma defined as Stage M1C or elevated LDH:

  • Stage M1c describes the situation where a patient’s melanoma has spread beyond the lungs to other organs or sites around the body
  • elevated LDH (lactic dehydrogenase) is an enzyme found in blood at increased levels when healthy tissue is damaged. LDH levels are considered when staging advanced melanoma.

When used in combination:

  • Opdivo and Yervoy are administered together for the first four treatments, every 3 weeks (ie four treatments over 10 weeks)
  • Opdivo is then administered on its own every 2 weeks
  • Treatment is stopped if the cancer progresses or there are unacceptable side effects.

The combination of OPDIVO and YERVOY is approved by the Therapeutic Goods Administration (TGA) in Australia but not reimbursed on the Pharmaceutical Benefits Scheme (PBS).


Talimogene Laherparepvec (Imlygic or Tvec)

Imlygic is a genetically modified live oncolytic herpes virus designed to replicate within cancer cells and produce an immunostimulatory protein called GM-CSF (granulocyte-macrophage colony-stimulating factor).

Imlygic is injected directly into the melanoma tumour, causing cell lysis, or death, which ruptures the tumors, and releases tumor-derived antigens, which along with GM-CSF, may promote an anti-tumor immune response. However, the exact mechanism of action is unknown.
Imlygic is injected every 2 weeks for a period of 6 months at which point treatment ceases if there has been no response. Alternatively treatment continues until the tumours are no longer present.

Imlygic is a live virus and therefore proper handling and wound dressing is important. It presents a treatment option for a subset of patients that have comorbidities, are elderly and/or frail or that have a poor IV profile as it is well tolerated with few side effects.

This treatment is not available on the PBS at this time.


Interferon-alfa2b (interferon, IFN, Intron A)

Interferon is a naturally occurring protein that is part of the body’s immune system. Interferon used to treat melanoma is produced in a laboratory using genetic engineering.

Interferons are cytokines, which are chemicals produced by white blood cells in response to a virus, bacteria, or other foreign bodies. They attach to foreign cells and cause changes including slowing down the rate of cell division and reducing the ability of a tumour cell to protect itself from the immune system.

Interferon is usually given intravenously over one month and then subcutaneously to complete a 1-year period and is sometimes considered for Stage III melanoma (after surgery and free of disease) to reduce the likelihood of melanoma returning.

Side effects include severe flu like symptoms and fatigue.

The treatment is rarely used in Australia.

Stay Connected

Melanoma Patients Australia Ltd shared their post. ... See MoreSee Less

Are you still planning to attend MPA's Cairns melanoma forum? Please note bookings close today. Any questions, call us 1300 88 44 50

View on Facebook

The 'booty' just keeps on growing for our MPA Gala Dinner on 9 June. Buy your tickets at mpagaladinner2017.eventbrite.com/ and on the night you could be taking home a Soleil Pool Bar Signature Garden Tea for 6 thanks to Rydges Hotels & Resorts, cinema space for 24 at Blue Room Cinebar, a Henry Coughlin Photography experience & print or 4 passes for 9 holes at Holey Moley Golf Club (pic below).

Don't miss out on an arresting night of fun!
... See MoreSee Less

View on Facebook

This year's Palliative Care week theme is 'You matter, Your care matters. Palliative care can make a difference’.
So many of us confuse palliative care with end of life care, assuming that death is imminent if we are referred to palliative care. Palliative care embodies wholeness, peacefulness and enhanced quality of life-- pain and symptom management so that you can get on with living as well as you can until you can't. Whether this is for a day, a week or a year is irrelevant compared with the relief found when you can let go of fear and despair even for just 1 hour. Please call MPA 1300 88 44 50 in office hours for more information. #npcw
... See MoreSee Less

View on Facebook

Contact us

Head Office:
Level 8, East Wing
Wesley Research Institute
451 Coronation Dve, Auchenflower QLD 4066
PO Box 1771
Toowong BC QLD 4066

Phone: 1300 884 450
Mail: info@melanomapatients.org.au

Newsletter